微创二尖瓣手术中同期三尖瓣修复的手术决策因素
基于MIMVS国际注册登记回顾性分析1077例符合三尖瓣修复指征的患者,其中910例接受修复、167例未修复。多因素回归显示三尖瓣反流程度、NYHA分级、二尖瓣病变类型及机构实践影响决策;修复组ICU与住院时间更长,30天死亡率组间相似。
要点
- 多数符合指征者接受同期三尖瓣修复,但机构实践显著影响决策。
- 三尖瓣反流较轻、NYHA分级较低者更可能被省略修复。
- 修复组ICU及住院时间更长,30天死亡率组间无显著差异。
核心结论
- 微创二尖瓣手术中同期三尖瓣修复的预防性指征总体被遵循,但临床与机构因素强烈影响省略决策。
研究设计与样本
- 基于MIMVS国际注册登记的回顾性分析,覆盖欧洲、美国、亚洲和澳大利亚17个中心共7513例患者,其中1077例有同期三尖瓣修复指征,910例接受修复、167例未修复。
主要发现
- 修复组年龄更大(72 vs 67岁,P<0.001)、女性更多(53.8% vs 39.8%,P<0.001)、房颤率更高(70.1% vs 54%,P<0.001)。
- 修复组ICU时间(48 vs 23小时,P<0.001)和住院时间(11 vs 8天,P<0.001)更长,30天死亡率组间相似(4.3% vs 1.8%,P=0.2)。
- 修复组EuroSCORE II更高(2.9 vs 1.6,P<0.001)。
- 省略修复的关键因素包括无重度三尖瓣反流(中度反流OR 3.31;轻度反流OR 4.06)、较低NYHA分级(NYHA III-IV级OR 0.61)、二尖瓣病变类型(OR 0.38)及机构实践(SD 0.28)。
关键数值与推荐
- 中度三尖瓣反流省略修复的OR为3.31,轻度三尖瓣反流OR为4.06。
- NYHA III-IV级省略修复的OR为0.61。
- 二尖瓣病变类型省略修复的OR为0.38;机构实践SD为0.28。
临床怎么用
- 在微创二尖瓣手术中,对符合指南指征者应评估三尖瓣反流程度、NYHA分级及二尖瓣病变类型,同时注意机构实践差异对决策的影响。
局限性
- 回顾性注册登记分析,可能存在选择偏倚和未测量混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To identify factors influencing the decision to omit tricuspid valve repair in patients who meet guideline criteria for tricuspid valve repair undergoing minimally invasive mitral valve surgery (MIMVS). METHODS: A retrospective analysis was conducted using the MIMVS International Registry, covering 7513 patients from 17 centres in Europe USA, Asia and Australia. Of these, 1077 had an indication for tricuspid valve repair. Patients were stratified into two groups: those who underwent tricuspid valve repair (n = 910) and those who did not (n = 167). Multivariate logistic regression analysis was conducted to identify the factors associated with the decision to perform tricuspid valve repair. RESULTS: Patients who received tricuspid valve repair were older (72 vs 67 years, P < 0.001), more often female (53.8% vs 39.8%, P < 0.001) and had higher rates of atrial fibrillation (70.1% vs 54%, P < 0.001). Tricuspid valve repair was associated with longer ICU (48 vs 23 hours, P < 0.001) and hospital stays (11 vs 8 days, P < 0.001), but 30-day mortality was similar between groups (4.3% for tricuspid valve repair vs 1.8% for no tricuspid valve repair, P = 0.2). Patients undergoing tricuspid valve repair had higher EuroSCORE II (2.9 vs 1.6, P < 0.001). Key factors for omitting tricuspid valve repair included absence of severe tricuspid regurgitation (odds ratio [OR] 3.31 for moderate tricuspid regurgitation; OR 4.06 for mild tricuspid regurgitation), lower NYHA class (OR 0.61 for NYHA III-IV), and mitral valve disease type (OR 0.38) and institutional practices (SD 0.28). CONCLUSIONS: Prophylactic indications for concomitant tricuspid valve repair in MIMVS are generally followed. Clinical and institutional factors strongly influence the decision to omit the tricuspid procedure despite guideline recommendations. Adhering to guidelines may improve outcomes by standardizing treatment choices.
引用
- Gollmann-Tepeköylü C, Berretta P, Gerdisch M, et al. Surgical decision-making for concomitant tricuspid valve repair in minimally invasive mitral valve surgery. Eur J Cardiothorac Surg. 2025. PMID: 40674586. doi:10.1093/ejcts/ezaf201
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。